CAR-T cells have yielded unprecedented efficacy in B cell malignancies, most remarkably anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate.

The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the success, more and more preclinical experiments and Phase I-III trials will be performed on large groups. The distribution of CAR-T cells and Oncolytic Viruses in the tumor and in the body is important for assessing the antitumor effect and safety of the injected CAR-T or Oncolytic Viruses in vivo, while observing the antitumor effect. Because of the heterogeneity of the tumor, the in situ localization and distribution of CAR-T cells and oncolytic virus in tumor cells and tumor microenvironment can reflect the mechanism and application prospect of the treatment method.

As CAR-T and oncolytic viruses themselves carry their own unique nucleic acid sequences, RNA specific probes designed for these regions can effectively detect the distribution of these cells or viruses in situ. So RNA ISH is a unique and effective tool for detecting CAR T cells and viruses in situ.

With years of professional experience in the RNA ISH Probe and ISH Service field, Creative Bioarray's streamlined process can offer timely and dependable in situ detection of CAR-T and Oncolytic Viruses results, giving you the flexibility to focus on other research priorities.

Applications

• In Situ detect the distribution of CAR-T cells/Oncolytic Viruses in tumor cells or tissues
• Assess the antitumor effect and safety of the injected CAR-T or Oncolytic Viruses in vivo
• Confirm CAR expression in FFPE tissue
• Quantify the CAR expression in FFPE tissue